Evidence map›Paper›PMID 22552984›Full record

ArticlePharmacoepidemiology and drug safety2012

Confronting "confounding by health system use" in Medicare Part D: comparative effectiveness of propensity score approaches to confounding adjustment.

Jennifer M Polinski, Sebastian Schneeweiss, Robert J Glynn, Joyce Lii, Jeremy A Rassen

Open access · greenAbstract read
In one paragraph

Article in Pharmacoepidemiology and drug safety, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pharmaceutical policies: effects of regulating drug insurance schemes.The Cochrane database of systematic reviews · 2022
    Pooled it
  2. Article
  3. Risk of liver dysfunction with ACE inhibitors based on real-world data from the MID-NETHypertension research : official journal of the Japanese Society of Hypertension · 2025
    Article
  4. Article
  5. Article
  6. Observational
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jennifer M PolinskiDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, USA. jpolinski@partners.org
Sebastian Schneeweiss
Robert J Glynn
Joyce Lii
Jeremy A Rassen
Brigham and Women's Hospital · USHarvard University · US

Funding

TRAINING PROGRAM IN EPIDEMIOLOGIC RESEARCH ON AGINGT32AG000158 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI GAZIANO, J. MICHAEL · 1988 to 2015
$2.1M
Analyzing Complex Healthcare Data to Determine Causality of Observed Drug EffectsR01LM010213 · NLM · BRIGHAM AND WOMEN'S HOSPITAL · PI SCHNEEWEISS, SEBASTIAN G. · 2009 to 2012
$1.6M
Impact of Medicare Drug Coverage on Antidepressant Quality and OutcomesU01MH079175 · NIMH · BRIGHAM AND WOMEN'S HOSPITAL · PI SCHNEEWEISS, SEBASTIAN G. · 2007 to 2010
$1.6M
Comparative effectiveness methods for evaluation of in-hospital exposuresK01HS018088 · AHRQ · BRIGHAM AND WOMEN'S HOSPITAL · PI RASSEN, JEREMY A · 2009 to 2012
$537k
AHRQ HHS K01 HS018088NIA NIH HHS T32 AG000158NIMH NIH HHS R01 5U01MH079175-02NIMH NIH HHS U01 MH079175NLM NIH HHS R01 LM010213
6 · The paper itself

Abstract

purposeUnder Medicare Part D, patient characteristics influence plan choice, which in turn influences Part D coverage gap entry. We compared predefined propensity score (PS) and high-dimensional propensity score (hdPS) approaches to address such "confounding by health system use" in assessing whether coverage gap entry is associated with cardiovascular events or death.

methodsWe followed 243,079 Medicare patients aged 65+ years with linked prescription, medical, and plan-specific data in 2005-2007. Patients reached the coverage gap and were followed until an event or year's end. Exposed patients were responsible for drug costs in the gap; unexposed patients (patients with non-Part D drug insurance and Part D patients receiving a low-income subsidy) received financial assistance. Exposed patients were 1:1 PS-matched or hdPS-matched to unexposed patients. The PS model included 52 predefined covariates; the hdPS model added 400 empirically identified covariates. Hazard ratios for death and any of five cardiovascular outcomes were compared. In sensitivity analyses, we explored residual confounding using only low-income subsidy patients in the unexposed group.

resultsIn unadjusted analyses, exposed patients had no greater hazard of death (HR = 1.00; 95%CI, 0.84-1.20) or other outcomes. PS-matched (HR = 1.29; 0.99-1.66) and hdPS-matched (HR = 1.11; 0.86-1.42) analyses showed elevated but non-significant hazards of death. In sensitivity analyses, the PS analysis showed a protective effect (HR = 0.78; 0.61-0.98), whereas the hdPS analysis (HR = 1.06; 0.82-1.37) confirmed the main hdPS findings.

conclusionAlthough the PS-matched analysis suggested elevated but non-significant hazards of death among patients with no financial assistance during the gap, the hdPS analysis produced lower estimates that were stable across sensitivity analyses.

Indexed as

Insurance CoverageMedicare Part DPropensity ScoreAgedAged, 80 and overCardiovascular DiseasesCohort StudiesConfounding Factors, EpidemiologicDrug UtilizationFemaleHumansMaleMortalityPovertyPrescription DrugsProspective StudiesPrescription Drugs

Identifiers

PMID22552984
PMCPMC3367305
OpenAlexW1528805520

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.